Join

Compare · NHF vs PPH

NHF vs PPH

Side-by-side comparison of NexPoint Strategic Opportunities Fund (NHF) and VanEck Vectors Pharmaceutical ETF (PPH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NHF and PPH operate in n/a (n/a), so they compete in similar markets.
  • NHF carries a market cap of $542.3M.
MetricNHFPPH
Company
NexPoint Strategic Opportunities Fund
VanEck Vectors Pharmaceutical ETF
Price
$14.65-0.54%
$100.20-1.02%
Market cap
$542.3M
-
1M return
-
-2.32%
1Y return
-
+14.61%
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NYSE
NASDAQ
IPO
n/a
n/a
News (4w)
0
0
Recent ratings
0
0
NHF

NexPoint Strategic Opportunities Fund

NexPoint Strategic Opportunities Fund is a closed ended balanced mutual fund launched by Highland Capital Management, L.P. It is managed by Nexpoint Advisors, L.P. The fund invests in the fixed income markets of the United States. It invests in companies across broadly diversified sectors to construct its portfolio. The fund typically invests in senior loans, secured and unsecured floating and fixed rate loans, bonds, debt obligations of stressed, distressed, and bankrupt issuers, mortgage-backed securities, asset-backed securities, and collateralized debt obligations with a primary focus on below investment grade debt and equity securities. It employs a quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Dow Jones Credit Suisse Hedge Fund and the HFRX Global Hedge Fund. It was formerly known as NexPoint Credit Strategies Fund. NexPoint Strategic Opportunities Fund was formed on June 1, 2006 and is domiciled in the United States.

PPH

VanEck Vectors Pharmaceutical ETF

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.